A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
PHASE2
This study is a multicenter, prospective, randomized controlled Phase II cl...
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
PHASE3
HS-10241, an oral and highly selective MET-TKI, may contribute to overcomin...
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
PHASE2
This is a prospective, multi-center, open-label, single-arm, non-randomized...
Status
Completed
Location
University of South Alabama / Mitchell Cancer Institute Univ South Alabama
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
PHASE3
Global, Phase 3, randomized, multicenter, open-label study evaluating the e...